ANTIARRHYTHMIC EFFECTS OF RANOLAZINE IN PATIENTS WITH CARDIAC ARRHYTHMIAS  by Assadi, Hamid Reza et al.
A336
JACC April 1, 2014
Volume 63, Issue 12
Arrhythmias and Clinical EP
antiarrhythmic EffEcts of ranoLazinE in patiEnts with cardiac arrhythmias
Poster Contributions
Hall C
Saturday, March 29, 2014, 3:45 p.m.-4:30 p.m.
Session Title: Arrhythmias and Clinical EP: Other I
Abstract Category: 6. Arrhythmias and Clinical EP: Other
Presentation Number: 1141-91
Authors: Hamid Reza Assadi, Hossein Shenasa, Shahriar Heidary, Mohammad Shenasa, Heart and Rhythm Medical Group, San Jose, CA, USA, 
Department of Cardiovascular Medicine, O’Connor Hospital, San Jose, CA, USA
background: Ranolazine (R) is approved for the management of chronic angina. R has been found to have multichannel blocking effects including 
the cardiac late sodium current, as well as inhibition of the rapid delayed-rectifier potassium current, which leads to an increased QT interval in a 
dose-related manner. We investigated the effect of R in patients with ventricular arrhythmias (VA) and supraventricular arrhythmias (SVA).
methods: We retrospectively analyzed the effect of R (500mg bid) in 28 patients with chronic angina (50% male) with mean age of 79±11 years. 
Holter monitors were obtained before and after R without any concomitant medication changes. The frequency of total number of VA, premature 
ventricular contractions, couplets, and non-sustained ventricular tachycardia were measured. The total number SVA, premature atrial contractions 
(PAC), pairs, supraventricular tachycardia (SVT), longest SVT (beats), fastest SVT (beats/minute), and episodes of atrial fibrillations were also 
measured.
results: Ventricular Tachycardia and Atrial Fibrillation, which was present in 4% and 14% of patients, respectively, completely resolved. The effects 
of R on VA and SVA are summarized in the table below:
VA SVA
PVC Couplets VT Total PAC Pair SVT Longest SVT (beats) Fastest SVT (beats/min) AF
Before 539 14.6 0.04 659.7 149 8.0 7.3 5.5 134 0.14
After 287 3.7 0 65.5 42.2 1.3 0.9 1.5 105 0
P-Value 0.59 0.036 0.33 0.008 0.038 0.005 0.01 0.014 0.015 0.1
conclusions: To our knowledge this is the first report of the role of R in suppressing VA and SVA in patients with chronic stable angina. Larger 
randomized prospective trials are warranted.
